Caprock Group LLC Takes Position in IDEXX Laboratories, Inc. $IDXX

Caprock Group LLC purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, HoldingsChannel reports. The firm purchased 7,721 shares of the company’s stock, valued at approximately $4,996,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. ING Groep NV bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $215,000. Advisors Asset Management Inc. increased its stake in IDEXX Laboratories by 3.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,521 shares of the company’s stock valued at $1,611,000 after purchasing an additional 75 shares in the last quarter. Krilogy Financial LLC acquired a new position in IDEXX Laboratories during the third quarter worth $2,587,000. Stratos Wealth Partners LTD. raised its holdings in IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock worth $683,000 after buying an additional 18 shares during the last quarter. Finally, Midwest Trust Co lifted its stake in shares of IDEXX Laboratories by 760.2% in the third quarter. Midwest Trust Co now owns 13,781 shares of the company’s stock valued at $8,805,000 after buying an additional 12,179 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $648.73 on Thursday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98. The firm has a 50-day moving average of $688.69 and a 200 day moving average of $666.93. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm has a market cap of $51.80 billion, a P/E ratio of 49.64, a PEG ratio of 3.93 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.15. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the company earned $2.53 earnings per share. The company’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IDXX. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 7th. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $783.33.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.